MktsMarkets

Nautilus Biotechnology, Inc.
NASDAQ: NAUTKey statistics
NAUT News
Stories mentioning NAUT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 9,707 | 9,575 | 9,605 | 10,394 | 11,536 | 12,823 | 12,288 | 12,436 |
| Sales General & Admin | 6,417 | 7,308 | ||||||
| Total Operating Expenses | 16,124 | 15,424 | 15,472 | 17,097 | 18,844 | 19,980 | 19,100 | 20,789 |
| Operating Income (Loss) | ||||||||
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (14,697) | (13,781) | (13,574) | (15,033) | (16,613) | (17,594) | (16,446) | (18,010) |
| Earnings Per Share (Basic) | (0.12) | (0.11) | (0.11) | (0.12) | (0.13) | (0.14) | (0.13) | (0.14) |
| Earnings Per Share (Diluted) | (0.12) | (0.11) | (0.11) | (0.12) | (0.13) | (0.14) | (0.13) | (0.14) |
| Weighted Average Shares Outstanding (Basic) | 126,635 | 126,257 | 126,305 | 126,205 | 126,144 | 125,427 | 125,453 | 125,318 |
| Weighted Average Shares Outstanding (Diluted) | 126,635 | 126,257 | 126,305 | 126,205 | 126,144 | 125,427 | 125,453 | 125,318 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NAUT
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a stock listed on the Nasdaq Stock Market under the ticker symbol NAUT. It last traded at $2.21 (Nov 5, 2026, 10:10 AM ET), down 3.5% on the day. That gives Nautilus Biotechnology a market capitalisation of $291.7M.
Over the past 52 weeks NAUT has traded between $0.8400 and $4.31.
For the quarter ended Mar 31, 2026 it reported a net loss of $14.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$14.7M |
| Dec 31, 2025 | — | -$13.8M |
| Sep 30, 2025 | — | -$13.6M |
| Jun 30, 2025 | — | -$15.0M |
From Nautilus Biotechnology’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…